Advertisement

Related Videos

Boon-Cher Goh, MD, on Cancer Drugs in Singapore: 3As (Availability, Accessibility, and Affordability)

Opportunities to Optimize Cancer Policies Panel Discussion

Ian Tannock, MD, PhD, DSc, on Near-Equivalence: A Better Question Than Non-Inferiority

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Alternative Dispensing Strategies

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Advertisement

Advertisement




Feb
26
Today In Oncology
Advanced Nonsquamous NSCLC FDA Grants Accelerated Approval to Zongertinib
Long-Term Health Risks for Testicular Cancer Survivors Differ by Chemotherapy Regimen
Cancer Diagnoses During COVID-19 Pandemic: Impact on 1-Year Cause-Specific Survival
‘Prostate Screening Saved My Life’—Is That Really True In Most Cases?
Effect of Medicaid Expansion on Diagnosis, Treatment, and Outcomes in NSCLC
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo